Sven Wegner

902 total citations
31 papers, 517 citations indexed

About

Sven Wegner is a scholar working on Immunology, Dermatology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Sven Wegner has authored 31 papers receiving a total of 517 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 10 papers in Dermatology and 7 papers in Cellular and Molecular Neuroscience. Recurrent topics in Sven Wegner's work include Psoriasis: Treatment and Pathogenesis (15 papers), Dermatology and Skin Diseases (10 papers) and Circadian rhythm and melatonin (6 papers). Sven Wegner is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (15 papers), Dermatology and Skin Diseases (10 papers) and Circadian rhythm and melatonin (6 papers). Sven Wegner collaborates with scholars based in Germany, United Kingdom and France. Sven Wegner's co-authors include Hugh D. Piggins, Mino D. C. Belle, Ernesto J. Muñoz‐Elías, C. Paul, Christian Derst, Timothy M. Brown, Kilian Eyerich, Andreas Pinter, Antonio Costanzo and Kristian Reich and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Neuroscience and SHILAP Revista de lepidopterología.

In The Last Decade

Sven Wegner

26 papers receiving 516 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sven Wegner Germany	13	233	164	128	118	108	31	517
Kyle A. Lyman United States	12	56 0.2×	99 0.6×	176 1.4×	145 1.2×	51 0.5×	26	444
Seulah Choi United States	9	105 0.5×	85 0.5×	47 0.4×	62 0.5×	211 2.0×	13	442
Christine Windemuth Germany	9	165 0.7×	45 0.3×	65 0.5×	77 0.7×	72 0.7×	14	402
C Kamei Japan	8	236 1.0×	10 0.1×	89 0.7×	178 1.5×	42 0.4×	28	384
Jeremy J. Stubblefield United States	10	116 0.5×	14 0.1×	51 0.4×	197 1.7×	278 2.6×	11	750
Philippe Fonjallaz Switzerland	6	28 0.1×	11 0.1×	93 0.7×	127 1.1×	120 1.1×	8	487
Julie A. McLachlan United States	7	124 0.5×	8 0.0×	62 0.5×	88 0.7×	86 0.8×	7	412
Margaret L. Entwistle United States	10	55 0.2×	22 0.1×	99 0.8×	194 1.6×	169 1.6×	11	1.1k
Jean-Daniel Doutremepuich France	5	37 0.2×	47 0.3×	352 2.8×	239 2.0×	170 1.6×	8	467
David-Marian Otte Germany	9	83 0.4×	8 0.0×	122 1.0×	94 0.8×	39 0.4×	11	363

Countries citing papers authored by Sven Wegner

Since Specialization

Citations

This map shows the geographic impact of Sven Wegner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sven Wegner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sven Wegner more than expected).

Fields of papers citing papers by Sven Wegner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sven Wegner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sven Wegner. The network helps show where Sven Wegner may publish in the future.

Co-authorship network of co-authors of Sven Wegner

This figure shows the co-authorship network connecting the top 25 collaborators of Sven Wegner. A scholar is included among the top collaborators of Sven Wegner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sven Wegner. Sven Wegner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Beeh, Kai Michael, Enrico Heffler, Hartmut Timmermann, et al.. (2025). Device adherence and user experience with daily home-based FeNO monitoring (Vivatmo me) in asthma patients: the FeNO@home observational study. SHILAP Revista de lepidopterología. 3(1).

Puig, L., Antonio Costanzo, E.M.G.J. de Jong, et al.. (2024). Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial. Dermatology and Therapy. 14(9). 2539–2558.

Kiper, Aytuğ K., Sven Wegner, Susanne Rinné, et al.. (2024). KCNQ1 is an essential mediator of the sex-dependent perception of moderate cold temperatures. Proceedings of the National Academy of Sciences. 121(25). e2322475121–e2322475121. 4 indexed citations

Egeberg, Alexander, et al.. (2024). Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials. Dermatology and Therapy. 14(3). 745–758. 1 indexed citations

Chen, Ye, Julianty Angsana, Nadine Krüger, et al.. (2024). LB943 Prediction of super response and drug-free disease control in guselkumab patients using multivariate baseline serum biomarkers: data from part 3 of GUIDE trial. Journal of Investigative Dermatology. 144(8). S165–S165. 1 indexed citations

Kirby, Brian, Andrea Chiricozzi, Jozefien Buyze, et al.. (2024). Time to Loss of Disease Control following Guselkumab Withdrawal in Relation to Initial Speed of Response: A post hoc Analysis of the VOYAGE 2 Trial. Dermatology. 241(2). 133–142. 2 indexed citations

Asadullah, Khusru, Knut Schäkel, Andreas Pinter, et al.. (2024). 49730 GUIDE trial (part 3): Following guselkumab withdrawal and a long treatment-free period, disease control is rapidly regained upon re-treatment in psoriasis super-responders. Journal of the American Academy of Dermatology. 91(3). AB222–AB222.

Gerdes, Sascha, Matthias Hoffmann, K. Asadullah, et al.. (2023). Effectiveness, safety and quality‐of‐life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non‐interventional, prospective, German multicentre PERSIST study. Journal of the European Academy of Dermatology and Venereology. 39(S1). 38–49. 8 indexed citations

Thaçi, Diamant, Andreas Pinter, Michael Sebastian, et al.. (2023). Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS). British Journal of Dermatology. 191(1). 36–48. 1 indexed citations

10.

Schäkel, Knut, Kristian Reich, K. Asadullah, et al.. (2023). Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study. Journal of the European Academy of Dermatology and Venereology. 37(10). 2016–2027. 46 indexed citations

11.

Tillett, William, Alexander Egeberg, Enikö Sonkoly, et al.. (2023). Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial. Arthritis Research & Therapy. 25(1). 169–169. 3 indexed citations

12.

Gerdes, Sascha, K. Asadullah, Matthias Hoffmann, et al.. (2022). Real‐world evidence from the non‐interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab. Journal of the European Academy of Dermatology and Venereology. 36(9). 1568–1577. 16 indexed citations

13.

Asadullah, K., et al.. (2022). 083 Prolonged Q16W treatment interval of guselkumab is non-inferior to Q8W dosing for maintaining disease control in super responders: primary results from GUIDE at Week 68 in patients with psoriasis. Journal of Investigative Dermatology. 142(12). S194–S194. 2 indexed citations

14.

Hughes, Alun T. L., Beatriz Baño‐Otálora, Mino D. C. Belle, et al.. (2021). Timed daily exercise remodels circadian rhythms in mice. Communications Biology. 4(1). 761–761. 37 indexed citations

15.

Eyerich, Kilian, Peter Weisenseel, Andreas Pinter, et al.. (2021). IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open. 11(9). e049822–e049822. 54 indexed citations

16.

Gerdes, Sascha, et al.. (2021). Real‐world effectiveness of guselkumab in patients with psoriasis: Health‐related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial. The Journal of Dermatology. 48(12). 1854–1862. 32 indexed citations

17.

Wegner, Sven, Mino D. C. Belle, Alun T. L. Hughes, Casey O. Diekman, & Hugh D. Piggins. (2017). Delayed Cryptochrome Degradation Asymmetrically Alters the Daily Rhythm in Suprachiasmatic Clock Neuron Excitability. Journal of Neuroscience. 37(33). 7824–7836. 12 indexed citations

18.

Guilding, Clare, Fiona Scott, David A. Bechtold, et al.. (2012). Suppressed cellular oscillations in after‐hours mutant mice are associated with enhanced circadian phase‐resetting. The Journal of Physiology. 591(4). 1063–1080. 19 indexed citations

19.

Derst, Christian, et al.. (2011). RNA editing of Kv1.1 channels may account for reduced ictogenic potential of 4-aminopyridine in chronic epileptic rats. Epilepsia. 52(3). 645–648. 34 indexed citations

20.

Musset, Boris, Sven G. Meuth, Christian Derst, et al.. (2006). Effects of divalent cations and spermine on the K⁺channel TASK‐3 and on the outward current in thalamic neurons. The Journal of Physiology. 572(3). 639–657. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact